Participated in Ambrosia Biosciences' $100M Series B for cardiometabolic therapeutics.
Ambrosia Biosciences is a drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders
Ambrosia Biosciences is a drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders. The company integrates cryo-EM-enabled structural biology, biophysical binding assays, and AI-powered molecular design to accelerate GPCR drug discovery.